S1 is named as a drug or biological intervention in 7 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Yu jiren (3), National Health Research Institutes, Taiwan (1) and Qilu Hospital of Shandong University (1). Registered phase: Phase 2. Conditions studied include Adenocarcinoma of the Stomach; Adenocarcinoma of Esophagogastric Junction; Phase II, Open-label, Parallel 2-arm, Multi-center.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Adenocarcinoma of the Stomach | 3 |
| Adenocarcinoma of Esophagogastric Junction | 3 |
| Phase II, Open-label, Parallel 2-arm, Multi-center | 1 |
| HER2-positive Gastric Cancer | 1 |
| Proficient Mismatch Repair | 1 |
| Gastric Cancer | 1 |
| Gastro Esophageal Junction Cancer | 1 |
| Mismatch Repair Deficiency | 1 |
| Esophageal Cancer | 1 |
| Epstein-Barr Virus-Associated Gastric Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Yu jiren | 3 |
| National Health Research Institutes, Taiwan | 1 |
| Qilu Hospital of Shandong University | 1 |
| Fudan University | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Register | S1 trials |
|---|---|
| Clinical trials in China | 7 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how S1 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists S1 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.